JP2005506294A5 - - Google Patents

Download PDF

Info

Publication number
JP2005506294A5
JP2005506294A5 JP2002574974A JP2002574974A JP2005506294A5 JP 2005506294 A5 JP2005506294 A5 JP 2005506294A5 JP 2002574974 A JP2002574974 A JP 2002574974A JP 2002574974 A JP2002574974 A JP 2002574974A JP 2005506294 A5 JP2005506294 A5 JP 2005506294A5
Authority
JP
Japan
Prior art keywords
tegafur
use according
uracil
administered
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002574974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506294A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/006262 external-priority patent/WO2002076459A1/en
Publication of JP2005506294A publication Critical patent/JP2005506294A/ja
Publication of JP2005506294A5 publication Critical patent/JP2005506294A5/ja
Pending legal-status Critical Current

Links

JP2002574974A 2001-03-06 2002-03-04 テガフル、ウラシル、フォリン酸、パクリタキセルおよびカルボプラチンの投与による腫瘍の治療方法および剤形 Pending JP2005506294A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27357701P 2001-03-06 2001-03-06
PCT/US2002/006262 WO2002076459A1 (en) 2001-03-06 2002-03-04 Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin

Publications (2)

Publication Number Publication Date
JP2005506294A JP2005506294A (ja) 2005-03-03
JP2005506294A5 true JP2005506294A5 (https=) 2005-12-22

Family

ID=23044526

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002574974A Pending JP2005506294A (ja) 2001-03-06 2002-03-04 テガフル、ウラシル、フォリン酸、パクリタキセルおよびカルボプラチンの投与による腫瘍の治療方法および剤形

Country Status (20)

Country Link
US (1) US6770653B2 (https=)
EP (1) EP1368034A1 (https=)
JP (1) JP2005506294A (https=)
KR (1) KR20030081496A (https=)
BR (1) BR0207443A (https=)
CA (1) CA2439676A1 (https=)
CZ (1) CZ20032266A3 (https=)
EE (1) EE200300429A (https=)
HR (1) HRP20030801A2 (https=)
HU (1) HUP0303466A3 (https=)
IL (1) IL157357A0 (https=)
IS (1) IS6925A (https=)
MX (1) MXPA03007989A (https=)
NO (1) NO20033910L (https=)
PL (1) PL363967A1 (https=)
RU (1) RU2284184C2 (https=)
SK (1) SK10602003A3 (https=)
WO (1) WO2002076459A1 (https=)
YU (1) YU69903A (https=)
ZA (1) ZA200306541B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
CN1761665A (zh) 2003-03-14 2006-04-19 大鹏药品工业株式会社 抗肿瘤效果增强剂和抗肿瘤剂
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
EP1827500B1 (en) * 2004-10-26 2009-05-06 Pharma Mar S.A., Sociedad Unipersonal Pegylated liposomal doxorubicin in combination with ecteinescidin 743
ATE368461T1 (de) 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2008202078B2 (en) * 2007-10-10 2012-05-31 Wellkey Holdings Limited Stability of secondary metabolite mass production through synchronized plant cell cultures
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
US20180085377A1 (en) * 2015-04-22 2018-03-29 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
IL265044B2 (en) 2016-08-31 2025-02-01 Fujifilm Corp An antitumor preparation containing the substances nab-paclitaxel and 1-(2-deoxy-2-fluoro-4-thio-D-beta-arabinofurnosyl)cytosine, a kit containing these substances and their uses
RU2646450C1 (ru) * 2017-05-11 2018-03-05 Владимир Михайлович Курусин Способ лечения предраковых и ранних стадий раковых заболеваний желудка
WO2019146130A1 (ja) 2018-01-29 2019-08-01 富士フイルム株式会社 胆道がん用抗腫瘍剤および胆道がんの処置方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4328229A (en) 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5534513A (en) 1991-09-05 1996-07-09 Taiho Pharmaceutical Company, Ltd. Antitumor potentiator and antitumor composition
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
RU2194541C1 (ru) * 2001-07-13 2002-12-20 Научно-исследовательский институт онкологии Томского научного центра СО РАН Способ комбинированного лечения больных местнораспространенным раком желудка

Similar Documents

Publication Publication Date Title
JP2005506294A5 (https=)
RU2003129527A (ru) Способ и дозированная форма для опухолей путем введения тегафура, урацила, фолиновой кислоты, паклитаксела и карбоплатины
ES2630002T5 (es) Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa
US9814724B2 (en) Antitumor effect potentiator and antitumor agent
JP2004534850A5 (https=)
JP2019503365A5 (https=)
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
JP2009514874A5 (https=)
FI3457135T3 (fi) Fabryn taudin hoitovaihtoehtoja
JP2002523502A5 (https=)
JPH10279482A (ja) ピリミジン誘導体の単独で又は他の治療方法と組み合わせた癌の予防のための使用
JP2007501809A5 (https=)
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
JP2002525323A5 (https=)
US20210177850A1 (en) Method for treating cancer patients with severe renal impairment
JP2004533434A5 (https=)
CA2641713A1 (en) Hydrate forms of amg706
NZ514014A (en) Method of treating sleep apnoea
JP2002536333A5 (https=)
SI1634595T1 (sl) N-fenilbenzamidni derivati kot zdravila za zdravljenje kronične obstruktivne pljučne bolezni (KOPB)
JP2004533434A (ja) テガフール、ウラシル、フォリン酸およびシクロホスファミドの投与による腫瘍の治療方法
RU97112236A (ru) Способ лечения злокачественных опухолей кости и метастазов в кость остеолитического характера
RU2007111754A (ru) Применение мидостаурина для лечения желудочно-кишечных стромальных опухолей
JP2007516296A5 (https=)
Patel et al. Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: A report from the Children's Cancer Study Group